Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc.. Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.

To receive more information regarding the investigation of Alpine Immune Sciences, Inc. please fill out the form below.